Literature DB >> 1445805

Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immunodeficiency syndrome.

J E Merrill1.   

Abstract

While certain cytokines such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-alpha), IL-6, and transforming growth factor-beta (TGF-beta) may be involved in pro- and anti-inflammatory events in the central nervous system (CNS) of patients with multiple sclerosis (MS) and CNS acquired immunodeficiency syndrome (AIDS), there is not uniform consensus as to whether they are elevated or even detectable in all compartments of the body such as serum, cerebrospinal fluid (CSF), and tissue. Furthermore, if they are elevated in these diseases, there are no data as to whether they regulate the disease process itself. Myelin damage in MS is a punctate demyelination; in AIDS, it is a diffuse myelin pallor or dysmyelination. Oligodendrocytes are destroyed in MS but not CNS AIDS, suggesting a different mechanism for myelin loss in the two diseases. These different pathologies may provide clues about the role of macrophages, microglia, and/or the toxic products they produce in putatively giving rise to myelin damage. The stimuli that trigger such a destructive response by macrophages or glial cells and/or the regulation of the toxic events in the two diseases we would predict to be different. In MS, an effector cell-mediated lesion production and oligodendrocyte cell destruction seem to occur. We hypothesize that the effector is the inflammatory blood macrophage and/or microglial cell induced and promoted to its cytotoxic activity by a collaboration of neurotransmitters and cytokines. In CNS AIDS, virus-induced toxic products of glia and their diffusion through white and gray matter areas of the brain have been suggested. Such soluble mediators would then compromise metabolic processes of neurons and glia without widespread target cell loss.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445805     DOI: 10.1097/00002371-199210000-00004

Source DB:  PubMed          Journal:  J Immunother (1991)        ISSN: 1053-8550


  24 in total

1.  Inflammation in neuroviral diseases.

Authors:  Pascale Giraudon; Arlette Bernard
Journal:  J Neural Transm (Vienna)       Date:  2010-08       Impact factor: 3.575

Review 2.  Role of microglia in central nervous system infections.

Authors:  R Bryan Rock; Genya Gekker; Shuxian Hu; Wen S Sheng; Maxim Cheeran; James R Lokensgard; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 3.  Role of microglia in neuronal degeneration and regeneration.

Authors:  Lisa Walter; Harald Neumann
Journal:  Semin Immunopathol       Date:  2009-09-09       Impact factor: 9.623

4.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

5.  Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease?

Authors:  Caroline Jefferies; Claire Wynne; Rowan Higgs
Journal:  Nat Rev Immunol       Date:  2011-08-25       Impact factor: 53.106

6.  Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication.

Authors:  Gwyneth Zai; Daniel J Müller; Jan Volavka; Pal Czobor; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy
Journal:  Psychopharmacology (Berl)       Date:  2006-08-24       Impact factor: 4.530

Review 7.  Targeting Nuclear Factor-Kappa B Signaling Pathway by Curcumin: Implications for the Treatment of Multiple Sclerosis.

Authors:  Meysam Gachpazan; Sadra Habbibirad; Hoda Kashani; Tannaz Jamialahmadi; Hamid Reza Rahimi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Lipoic acid stimulates cAMP production via the EP2 and EP4 prostanoid receptors and inhibits IFN gamma synthesis and cellular cytotoxicity in NK cells.

Authors:  Sonemany Salinthone; Robynn V Schillace; Gail H Marracci; Dennis N Bourdette; Daniel W Carr
Journal:  J Neuroimmunol       Date:  2008-06-17       Impact factor: 3.478

9.  Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis.

Authors:  Narender Nath; Musfiquidin Khan; Manjeet K Paintlia; Inderjit Singh; Md Nasrul Hoda; Shailendra Giri
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

10.  B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity.

Authors:  Tomasz Brudek; Tove Christensen; Lars Aagaard; Thor Petersen; Hans J Hansen; Anné Møller-Larsen
Journal:  Retrovirology       Date:  2009-11-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.